Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Research & Development (2023 - 2026)

ArriVent BioPharma has reported Research & Development over the past 4 years, most recently at $37.6 million for Q1 2026.

  • Quarterly results put Research & Development at $37.6 million for Q1 2026, down 38.62% from a year ago — trailing twelve months through Mar 2026 was $129.7 million (up 5.16% YoY), and the annual figure for FY2025 was $153.4 million, up 94.11%.
  • Research & Development reached $37.6 million in Q1 2026 per AVBP's latest filing, up from $32.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $61.3 million in Q1 2025 and bottomed at $10.2 million in Q1 2023.
  • Median Research & Development over the past 4 years was $20.4 million (2023), compared with a mean of $25.8 million.
  • The largest annual shift saw Research & Development soared 261.05% in 2025 before it tumbled 38.62% in 2026.
  • Over 4 years, Research & Development stood at $20.0 million in 2023, then grew by 0.76% to $20.2 million in 2024, then surged by 59.57% to $32.2 million in 2025, then grew by 16.91% to $37.6 million in 2026.
  • Business Quant data shows Research & Development for AVBP at $37.6 million in Q1 2026, $32.2 million in Q4 2025, and $32.2 million in Q3 2025.